BACKGROUND: Neutropenic patients are at risk of abdominal complications and yet the incidence and impact of these complications on patients' morbidity and mortality have not been sufficiently evaluated. We aimed to assess a clinical rule for early detection of abdominal complications leading to death or transfer to intensive care in patients with chemotherapy-associated neutropenia. DESIGN AND METHODS: This observational multicenter study was carried out in seven German hematology-oncology departments. For inclusion, neutropenia of at least 5 consecutive days was required. Risk factors for "transfer to intensive care" and "death" were assessed by backward-stepwise binary logistic regression analyses. Chemotherapy-associated bowel syndrome was defined as a combination of fever (T ≥37.8 °C) and abdominal pain and/or lack of bowel movement for 72 hours or more. Five hundred and twenty-one neutropenic episodes were documented in 359 patients. RESULTS: The incidence of chemotherapy-associated bowel syndrome was 126/359 (35%) in first episodes of neutropenia. Transfer to intensive care occurred in 41/359 (11%) and death occurred in 17/359 (5%) first episodes. Chemotherapy-associated bowel syndrome and duration of neutropenia were identified as risk factors for transfer to intensive care (P<0.001; OR 4.753; 95% CI 2.297-9.833, and P=0.003; OR 1.061/d; 95% CI 1.021-1.103). Chemotherapy-associated bowel syndrome and mitoxantrone administration were identified as risk factors for death (P=0.005; OR 4.611; 95% CI 1.573-13.515 and P=0.026; OR 3.628; 95% CI 1.169-11.256). CONCLUSIONS: The occurrence of chemotherapy-associated bowel syndrome has a significant impact on patients' outcome. In future interventional clinical trials, this definition might be used as a selection criterion for early treatment of patients at risk of severe complications.
BACKGROUND:Neutropenicpatients are at risk of abdominal complications and yet the incidence and impact of these complications on patients' morbidity and mortality have not been sufficiently evaluated. We aimed to assess a clinical rule for early detection of abdominal complications leading to death or transfer to intensive care in patients with chemotherapy-associated neutropenia. DESIGN AND METHODS: This observational multicenter study was carried out in seven German hematology-oncology departments. For inclusion, neutropenia of at least 5 consecutive days was required. Risk factors for "transfer to intensive care" and "death" were assessed by backward-stepwise binary logistic regression analyses. Chemotherapy-associated bowel syndrome was defined as a combination of fever (T ≥37.8 °C) and abdominal pain and/or lack of bowel movement for 72 hours or more. Five hundred and twenty-one neutropenic episodes were documented in 359 patients. RESULTS: The incidence of chemotherapy-associated bowel syndrome was 126/359 (35%) in first episodes of neutropenia. Transfer to intensive care occurred in 41/359 (11%) and death occurred in 17/359 (5%) first episodes. Chemotherapy-associated bowel syndrome and duration of neutropenia were identified as risk factors for transfer to intensive care (P<0.001; OR 4.753; 95% CI 2.297-9.833, and P=0.003; OR 1.061/d; 95% CI 1.021-1.103). Chemotherapy-associated bowel syndrome and mitoxantrone administration were identified as risk factors for death (P=0.005; OR 4.611; 95% CI 1.573-13.515 and P=0.026; OR 3.628; 95% CI 1.169-11.256). CONCLUSIONS: The occurrence of chemotherapy-associated bowel syndrome has a significant impact on patients' outcome. In future interventional clinical trials, this definition might be used as a selection criterion for early treatment of patients at risk of severe complications.
Authors: R Avery; B Pohlman; K Adal; B Bolwell; M Goldman; M Kalaycio; G Hall; S Andresen; S Mossad; S Schmitt; P Mason; D Longworth Journal: Bone Marrow Transplant Date: 2000-01 Impact factor: 5.483
Authors: M Gorschlüter; A Glasmacher; C Hahn; C Leutner; G Marklein; J Remig; I G Schmidt-Wolf; T Sauerbruch Journal: Cancer Invest Date: 2001 Impact factor: 2.176
Authors: M Gorschlüter; A Glasmacher; C Hahn; F Schakowski; C Ziske; E Molitor; G Marklein; T Sauerbruch; I G Schmidt-Wolf Journal: Clin Infect Dis Date: 2001-08-10 Impact factor: 9.079
Authors: Jeff A Sloan; Richard M Goldberg; Daniel J Sargent; Delfino Vargas-Chanes; Suresh Nair; Steven S Cha; Paul J Novotny; Michael A Poon; Michael J O'Connell; Charles L Loprinzi Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Natali Pflug; Sandra Kluth; Jörg J Vehreschild; Jasmin Bahlo; Daniela Tacke; Lena Biehl; Barbara Eichhorst; Kirsten Fischer; Paula Cramer; Anna-Maria Fink; Michael von Bergwelt-Baildon; Stephan Stilgenbauer; Michael Hallek; Oliver A Cornely; Maria J G T Vehreschild Journal: Oncoimmunology Date: 2016-04-22 Impact factor: 8.110
Authors: Oliver A Cornely; David Helfgott; Amelia Langston; Werner Heinz; Jörg-Janne Vehreschild; Maria J G T Vehreschild; Gopal Krishna; Lei Ma; Susan Huyck; Michael C McCarthy Journal: Antimicrob Agents Chemother Date: 2012-01-30 Impact factor: 5.191
Authors: Rafael F Duarte; Javier López-Jiménez; Oliver A Cornely; Michel Laverdiere; David Helfgott; Shariq Haider; Pranatharthi Chandrasekar; Amelia Langston; John Perfect; Lei Ma; Marlou L P S van Iersel; Nancy Connelly; Nicholas Kartsonis; Hetty Waskin Journal: Antimicrob Agents Chemother Date: 2014-07-21 Impact factor: 5.191
Authors: Walter K Kraft; Peter S Chang; Marlou L P S van Iersel; Hetty Waskin; Gopal Krishna; Wendy M Kersemaekers Journal: Antimicrob Agents Chemother Date: 2014-05-05 Impact factor: 5.191
Authors: M Schmidt-Hieber; J Bierwirth; D Buchheidt; O A Cornely; M Hentrich; G Maschmeyer; E Schalk; J J Vehreschild; Maria J G T Vehreschild Journal: Ann Hematol Date: 2017-11-24 Impact factor: 3.673
Authors: Fernanda Spadão; Juliana Gerhardt; Thais Guimarães; Frederico Dulley; João Nóbrega de Almeida Junior; Marjorie Vieira Batista; Maria Aparecida Shikanai-Yasuda; Anna Sara Levin; Silvia Figueiredo Costa Journal: Rev Inst Med Trop Sao Paulo Date: 2014 Jul-Aug Impact factor: 1.846